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Abstract
In chronic Trypanosoma cruzi infections, parasite burden is controlled by effective, but non-
sterilising immune responses. Infected cells are difficult to detect because they are scarce and 
focally distributed in multiple sites. However, advances in detection technologies have established 
a link between parasite persistence and the pathogenesis of Chagas heart disease. Long-term 
persistence likely involves episodic reinvasion as well as continuous infection, to an extent that 
varies between tissues. The primary reservoir sites in humans are not definitively known, but 
analysis of murine models has identified the gastrointestinal tract. Here, we highlight that 
quantitative, spatial and temporal aspects of T. cruzi infection are central to a fuller understanding 
of the association between persistence, pathogenesis and immunity, and for optimising treatment.
Beyond Parasite Persistence
The majority of people infected with Trypansoma cruzi survive the acute phase and progress 
to a chronic asymptomatic infection. Chagas cardiomyopathy is then estimated to develop at 
a rate of ~2% per year [1]. Megasyndromes of the gastrointestinal (GI) tract develop in a 
smaller proportion of cases, sometimes in combination with cardiac disease [2]. T. cruzi 
occurs predominantly in the form of intracellular amastigotes, which replicate in the cytosol 
of infected cells. These cells are scarce and focally distributed in a range of potential target 
tissues, making them difficult to detect. The apparent absence of parasites from heart tissue 
in many people affected by chronic chagasic cardiomyopathy [3, 4] contributed to Chagas 
disease being regarded as principally an autoimmune pathology. Over the past two decades 
the consensus has resoundingly changed. Few now support a purely autoimmune aetiology; 
strong evidence suggests that ongoing infection with T. cruzi is necessary to sustain the 
tissue damage characteristic of the disease. This idea was encapsulated within the parasite 
persistence hypothesis [5], which stated “the persistence of Trypanosoma cruzi at specific 
sites in the infected host results in chronic inflammatory reactivity”. The evidence base 
supporting the hypothesis is built on the detection of parasite-derived biomolecules (DNA, 
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antigen) in chagasic heart tissue [6, 7], the lack of autoimmune reactivity in the absence of 
concomitant infection [8], and the efficacy of early anti-parasitic chemotherapy [9]. The 
benefit of treatment is not apparent for those with late stage heart disease [10], most 
probably because cardiac damage is largely irreversible. The immunopathogenesis of 
chagasic cardiomyopathy has been comprehensively reviewed [11-14]; here we will focus on 
the causative agent.
Beyond the requirement that ongoing T. cruzi infection is necessary for the development of 
cardiomyopathy, little attention has been paid to the possible modes of parasite persistence 
within chronically infected individuals (Figure 1, Key Figure). Emerging evidence suggests 
that the intensity of infection can vary substantially between different tissues and over time, 
and that these dynamics may vary further between infected individuals. Multiple factors are 
likely to underpin this heterogeneity, including genetic diversity of the host and the infecting 
parasite strain(s) and environmental factors. The T. cruzi species comprises six major 
genetic subtypes (TcI–VI) that have suspected, though largely unproven, associations with 
many aspects of Chagas disease, including modes of transmission, tissue tropism, severity of 
outcomes and treatment efficacy (reviewed in [15]). It is likely that the cumulative effect of 
host-parasite interactions played out over many years, in multiple tissues, ultimately 
determines clinical outcomes. These include chronic cardiomyopathy of varying severity, 
digestive megasyndromes, acute meningoencephalitis, and most commonly, the long-term 
absence of recognized symptoms [2]. In this review, we discuss the spatial, temporal and 
quantitative dynamics of T. cruzi infections. We also explore why a deeper understanding of 
parasite persistence is necessary to explain the contribution of T. cruzi to Chagas disease 
pathogenesis and to inform the development of more effective treatment strategies.
Measuring Parasite Loads
The number of parasites and their anatomical location over the course of infection are key 
parameters. Most importantly, an accurate parasite load measurement, or proxy measure, 
helps to determine curative outcomes after therapeutic interventions (Box 1). There are a 
variety of techniques to detect and potentially quantify T. cruzi in tissue samples, each with 
benefits and drawbacks (Table 1). Detection sensitivity is a marginal concern in analyses of 
acute or reactivated infections when parasite loads are high, but becomes critical in the 
chronic phase, when parasite abundance is decreased by several orders of magnitude [16]. 
For example, extracellular, non-replicating trypomastigotes are routinely detectable in the 
blood for a period during acute infection and can be observed by light microscopy. However, 
these forms become rare after the host establishes control of the infection. Acute blood 
parasitaemia is not necessarily correlated with tissue parasite burdens or predictive of 
outcomes in the chronic phase. Isolation of live organisms can be achieved from fresh tissues 
using ex vivo parasite culturing techniques, and this generates enough material for genetic 
typing [17-19].
Clusters of T. cruzi amastigotes can be readily observed in tissue by histological staining. 
This allows visualisation of infected cells in situ and in the context of local pathology. In the 
chronic phase, such infected cells are typically scarce, which limits the scope of histology 
for parasite load estimation. Sensitivity can be improved in experimental studies through the 
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use of parasites expressing reporter genes such as lacZ β-galactosidase [20]. 
Immunohistochemistry has frequently been used to detect T. cruzi antigens in tissue 
sections. In some cases, this eases the difficulty of visualising intact trypomastigotes and 
lone amastigotes [21], but more often it reveals antigen in the absence of intact parasites 
[22]. The presence of these antigen deposits is presumed to indicate the remnants of recently 
destroyed organisms.
PCR-based methodology is a mainstay of parasite detection in both diagnostic and 
experimental settings. Two loci in particular, the nuclear 195 bp satellite and kinetoplast 
DNA minicircles, allow very high sensitivity because there are thousands of copies per 
genome. Quantitative PCR protocols allow estimates of parasite burdens and comparison 
across tissues; however, they may overestimate the number of viable parasites. The presence 
of organisms in blood can confound interpretations of tissue residence and repeated PCR 
assays can be necessary to ensure accurate results [6]. T. cruzi subtypes can be ascertained 
using PCR-based methods, but this generally requires analysis of lower copy-number genes 
[23]. The resulting reduction in sensitivity means that direct identification of parasite 
genotypes in chronic infections remains challenging. New detection tools continue to be 
developed. For example, nucleic acid aptamers to identify T. cruzi secreted antigens in 
serum may surpass the sensitivity of PCR [24], and lineage-specific serology has the 
potential to define historical exposure to different parasite subtypes [25].
Experimental studies with predictive animal models can generate insights into T. cruzi 
infection dynamics that are not possible in humans. The techniques mentioned above can be 
applied to animal samples at specific times post-infection, in combination with defined 
experimental parameters, e.g. genotypes, inocula or treatments. Broad tissue-type sampling 
can be easily conducted for groups of identically-treated animals, although in practice most 
animal studies concentrate on a limited set of tissues. Real-time imaging methods have also 
been developed that allow serial analysis of T. cruzi infections in individual mice [26-29]. 
These methods employ transgenic parasites expressing luciferases or fluorescent proteins, 
such that light signals emitted by parasites can be quantified and pinpointed to anatomical 
locations. The intensity of light emitted from tissue samples ex vivo can also be used as a 
proxy for parasite loads in specific organs. A key development was the introduction of a 
firefly luciferase gene engineered to emit longer wavelength light, which has enhanced 
tissue penetrating capacity [30, 31]. The use of T. cruzi expressing this red-shifted luciferase 
enabled highly sensitive imaging of chronically infected mice [16, 32-34]. Drawbacks 
include the high associated costs and, potentially, a reduced ability to detect parasites that 
are metabolically quiescent. Interpretation of imaging data also requires careful 
consideration of the light absorbing and scattering properties of different tissues. For 
example, peripheral infection foci in sites such as the skin will have a lower associated limit 
of detection than those in visceral organs.
In summary, there are now multiple sensitive approaches to detect and estimate numbers of 
T. cruzi in diverse tissue types. Emerging technologies could soon increase sensitivity 
further and generate new insights into the parasite’s biology in vivo. For example, aptamers 
[35] or spliced leader trapping [36] can potentially enrich samples for rare parasites or 
parasite-derived mRNAs, while ribosomal profiling [37], fluorescence dilution [38] and 
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isotope labelling [39] approaches could help differentiate between dormant and active 
parasites. In the following sections we review current understanding of T. cruzi infection 
dynamics and explore why the utility of the parasite detection techniques described above 
depends on appropriate tissue sampling strategies.
Acute Infection and Tropisms
Upon primary infection from the insect vector, metacyclic trypomastigotes invade various 
cell types local to the site of inoculation and transform into amastigotes, which then undergo 
multiple rounds of mitotic replication. This proceeds for approximately one week and is 
followed by differentiation into bloodstream trypomastigotes and host cell rupture. The 
release of motile trypomastigotes into the haemolymphatics permits systemic dissemination 
and the acute phase of infection continues until the immune response brings parasite loads 
under control several weeks later. T. cruzi has the ability to invade and replicate inside 
almost any type of nucleated mammalian cell in vitro. The broad range of infected organs 
was noted in the earliest autopsy studies of fatal acute T. cruzi infection [40]. Analyses of 
acutely infected mice have shown that diverse parasite strains indeed infect a huge array of 
cell types in virtually any tissue [16, 20-22, 26, 33, 41-47]. However, the relative abundance 
of parasites in different cell or tissue types varies greatly. Sites reported to harbour the 
highest acute infection intensities include skeletal, smooth and cardiac muscle, mononuclear 
phagocytes and adipose tissues. Conversely, T. cruzi is comparatively rare where the blood/
oxygen supply is poor, for example in osteocytes and chondrocytes [42], cartilage [41] and 
in immune-privileged sites including ovaries and testes [43]. It is worth making a distinction 
between cell and tissue types, which is possible with microscopic detection of parasites, but 
not with methods that analyse homogenized tissue samples or macro-scale imaging. For 
example, bioluminescence imaging readily identifies the GI tract and lung as sites of 
infection [16, 26], but not the infected cell types. Using histological analysis, Guarner et al. 
[21] also described lung infections and found that amastigotes were only localised to the 
muscular stratum of pulmonary blood vessels. Similarly, within the GI tract, amastigotes can 
be more easily found in the smooth myocytes or within the myenteric plexus, than in the 
submucosa [45].
Heterogeneity in site-specific infection intensities with different parasite strains resulted in 
the concept of tropism being applied to T. cruzi [45, 48, 49]. However, the presence or 
absence of T. cruzi in particular cells and tissues may also be influenced by factors other 
than innate parasite preferences. For example, the route of inoculation, the dose, and the 
occurrence of other infections could all act to determine which of the viable niches the 
parasite occupies in vivo. Notwithstanding these caveats, all T. cruzi strains appear to share 
the ability to replicate within muscle cells (myocytes), and “myotropic” is something of a 
default term. It has been suggested that the preference for muscle might be an adaptation to 
access myoglobin as a source of heme [50]. Myocytes may also be invaded preferentially 
due to their highly active plasma membrane repair pathway, which T. cruzi can hijack to 
facilitate invasion [51]. Variability has also been described between different muscles, for 
example, the Brazil strain (TcI) is associated with higher parasite burdens in skeletal than in 
cardiac muscle, for unknown reasons [52].
Lewis and Kelly Page 4
Trends Parasitol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A subset of strains, e.g. Y (TcII), have been described as reticulotropic because, in addition 
to infecting muscle, they have a greater capacity to parasitize both resident and 
inflammatory mononuclear phagocytes compared to other strains, at least in acutely infected 
mice [45, 48, 53]. Targeting these cell types allows these strains to infect a wider variety of 
tissues and may be related to increased virulence.
In some circumstances, T. cruzi is able to cross the blood-brain barrier, potentially leading to 
fatal meningoencephalitis. A subset of TcI strains, ~20%, have been associated with this 
phenotype in mice [44, 54, 55]. Nevertheless, central nervous system (CNS) infections in 
humans are rare; they tend to follow immunosuppression [56] and can be caused by other 
lineages [57, 58]. The data available are not sufficient to conclude whether CNS involvement 
is a consequence of parasite-intrinsic virulence factors, a result of increased host 
susceptibility, or a combination.
Elusively Reclusive: T. cruzi in the Chronic Phase
The heart
Evidence for parasite tropisms is based almost exclusively on acute infections. The long-
term dynamics of T. cruzi infection have remained vague because of the difficulty in 
detecting rare parasite foci during the chronic phase. This has limited progress in 
understanding factors that influence chronic parasite loads in the heart and their connection 
to pathogenesis. Histological studies typically identified T. cruzi amastigotes in fewer than 
30% of chagasic human hearts [3, 4, 59-64]. Higher sensitivity molecular detection methods 
indicated the presence of T. cruzi DNA or antigen at frequencies of 50 – 95% [6, 61, 65-70]. 
The presence of T. cruzi or derived material frequently co-occurs with myocarditis [65, 67, 
69, 70], but quantitative correlation has not been demonstrated. Importantly, inflammation is 
only one of several pathological processes that contributes to the development of chagasic 
heart disease. Limited data suggest that an association between infection dynamics and 
fibrosis or tissue re-modelling is absent [65, 71], and evidence is lacking for links to 
denervation and conduction or microvascular abnormalities. Comparative analyses of human 
cases tend to rest on the presence or absence of parasites in samples from small cohorts of 
patients who had died or required a heart transplant. Causation is therefore uncertain 
because parasite loads at these times may not accurately reflect the preceding asymptomatic 
and early symptomatic period.
Experimental studies have also generated valuable data. Non-human primates, dogs, rabbits, 
rats and guinea pigs are all useful to study chronic cardiac infection [72], but for practical 
and ethical reasons mice are by far the most commonly used models. Drawing firm 
conclusions from the existing literature is complicated by variations in experimental design. 
This includes widespread use of different strains of parasites and mice, inoculum sizes, 
routes of inoculation, end-points, methods of parasite detection and parameters for 
pathology. Only a few mouse models of chronic T. cruzi infection have been described that 
involve heart parasite burdens high enough for consistent detection using histology [73, 74]. 
Similar to some human data, Zhang and Tarleton [22] found that the presence of T. cruzi 
kDNA was qualitatively associated with co-localized inflammatory infiltrates, indicative of 
ongoing immune responses against parasites persisting within the hearts of chronically 
Lewis and Kelly Page 5
Trends Parasitol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
infected mice. Estimates of cardiac parasite loads made using qPCR range from below the 
limit of detection [16, 33], 2 – 80 per 50 ng of host DNA [52, 75], 20 per mg of tissue [76] 
to 1 per 200 host cells [77]. However, direct comparisons of qPCR loads with pathology at 
the level of individual animals have not been reported.
The recent application of real-time bioluminescence imaging to quantify tissue-specific 
parasite burdens in multiple mouse models has generated unexpected insights into the 
dynamics of chronic infections. For the CL Brener strain (TcVI), cardiac-localised parasite 
bioluminescence was not detected in C57BL/6, and only ~10% of BALB/c or C3H mice, but 
frequencies of 40%, 50% and 88% respectively, were detected for a TcI strain (JRcl4) [16, 
34]. Cardiac fibrosis was consistently observed, but there was no correlation with parasite 
loads in individual animals. The host-parasite genotype combinations used in these studies 
had differing frequencies of infection in multiple organs other than the heart (see below). 
Furthermore, models exhibiting the most broadly disseminated infections had significantly 
higher levels of cardiac fibrosis. This correlation, together with additional lines of evidence, 
implied that infection of the heart is likely to be sporadic and repetitive, rather than 
continuous, and to occur at a frequency determined by the overall systemic distribution of 
parasites [34] (Figure 2). Further work is required to validate this hypothesis and to 
determine whether it can help to explain the relationship between cardiac parasitism and 
pathogenesis.
Other Sites
In humans with established infections, T. cruzi is clearly not restricted to cardiac tissue. For 
example, approximately half of Chagas disease patients that receive heart transplants 
develop symptomatic reactivation of T. cruzi infection [78]. Transmission via infected blood 
transfusions and the practice of xenodiagnosis demonstrate that parasites can be present in 
the blood after the acute phase [2]. Parasitemia clearly fluctuates because PCR analysis is 
not consistently positive or negative in individuals over time [10]. T. cruzi can also cross the 
placenta leading to congenital transmission in ~5% of cases, with some geographic 
variability linked to T. cruzi genotype [79]. As outlined below, parasites have been detected 
in a wide of range of other organs, but whether any of these sites serve as genuine long-term 
reservoirs, or simply become transiently infected is far from clear.
Several cases of transmission caused by transplantation of livers or kidneys from 
seropositive donors have been recorded, although the risk is lower than for hearts [60]. 
Parasites can be frequently detected in skeletal muscle in some chronic mouse infection 
models [20, 52, 75, 80, 81]. This site is poorly documented in humans – some physiological 
abnormalities have been described, but not the presence of parasites or inflammation [82]. 
The smooth muscles of blood vessels have also been identified as a site of chronic infection. 
For example, parasites were detected in the central vein of the adrenal gland in several small 
autopsy studies at frequencies of 5% [6], 30% [4] and 50% [83]. Progressive multi-organ 
vasculitis has been reported in mice infected with the high virulence Colombiana (TcI) strain 
[84].
Adipose tissue has also been suggested as a site of persistence. T. cruzi readily parasitizes 
adipocytes in vitro and lipid rich tissues can have high parasite loads in acutely infected 
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mice [16, 41, 77, 85]. Indeed, adipose tissue was a major site of T. cruzi persistence 
associated with posaconazole treatment failure in acutely infected mice [33], and 
panniculitis (inflammation of the fatty subcutaneous tissue) is a common symptom of 
reactivated Chagas disease [78]. The majority of C3H mice with long-term TcI infections 
have parasites in adipose tissue [34, 77], but this is less frequent for other genotype 
combinations [34]. A small study that analysed subcutaneous fat samples from ten 
seropositive patients found that three of them contained T. cruzi kDNA [86]. It is not known 
which cell type(s) within adipose tissue harbour T. cruzi in chronically infected subjects, nor 
whether infection is continuous or sporadic.
T. cruzi might parasitize the peripheral, enteric and central nervous systems in settings other 
than acute or reactivated infection, but direct evidence from humans is scarce. Amastigotes 
have been found in the sciatic nerve and lumbar spinal cord of C3H mice 8-10 months post-
infection [20, 87]. Neuronal damage and loss within the affected organs are important 
features of both cardiac and digestive Chagas disease, but this is more likely to be collateral 
to active inflammation in adjacent tissue compartments [88].
Owing to the focal pleiotropism of T. cruzi, studies on persistence have frequently been 
associated with tissue sampling biases. The development of sensitive real-time imaging has 
largely overcome this issue, at least for mouse models. Recent work in our laboratory 
revealed that the GI tract, specifically the large intestine and stomach, is the predominant site 
of parasite persistence for multiple mouse-parasite genotype combinations [16, 34]. One 
reason for this may be a local trade-off between incentives for the host to limit parasite 
numbers and to avoid bacterial translocation, which can occur in an inflamed gut [89]. 
Particular features of the intestinal microenvironment that might contribute to T. cruzi 
persistence include macrophage populations that are refractory to activation, as well as high 
levels of IL-10 and abundant regulatory T cells, which dampen inflammatory responses [90, 
91]. These data raise the possibility that ongoing GI infection continuously contributes to the 
development of digestive forms of Chagas disease. A lack of data on chronic GI infections in 
humans means this will remain an open question (Box 2). Nevertheless, in the context of 
drug development strategies, it appears prudent to consider the ability of compounds to 
reach effective concentrations in GI tissues as an important parameter.
These imaging studies also identified T. cruzi in a variety of other sites, including the heart, 
lung, skeletal muscle, skin and visceral fat. Unlike the GI tract, these infection foci were 
only ever detected in a subset of animals. Different combinations of parasite and mouse 
strains were associated with varying levels of disseminated infection foci outside the GI 
tract, but without any evidence of differential tissue tropism. For example, C57BL/6 mice 
infected with a TcVI strain rarely had dissemination outside the gut, whereas C3H mice 
infected with a TcI strain typically had multiple systemic parasite foci. Importantly, models 
with a higher degree of dissemination had significantly more severe cardiac fibrosis - a key 
marker of Chagas cardiomyopathy [34] (Figure 2). These findings highlight the importance 
of understanding both tissue-specific interactions between host and parasite, as well as the 
potential interconnectedness of infection between sites over time.
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Re-Invasion as a Route to Parasite-Driven Cardiopathogenesis
Adaptive immune responses, particularly those mediated by CD8+ T cells, are critical to 
maintain a stable long-term host-parasite equilibrium [92]. Humans with reduced immune 
function (e.g. HIV co-infection or immunosuppressive treatment),typically have lowered 
ability to control T. cruzi and often experience pathology in atypical sites (CNS, skin, GI 
tract) [56-58, 93]. Antibody-mediated depletion of T cells leads to exacerbated heart parasite 
loads and myocarditis in mice [94], and chronically infected mice treated with the 
immunosuppressant cyclophosphamide experience rapid systemic expansion of parasite 
loads, which resembles the acute phase pattern of infection [34]. Therefore, the niches 
available for T. cruzi within the chronically infected host are primarily defined by host 
responses rather than parasite tropism.
The dynamic nature of chronic phase parasite distribution means it is important to 
distinguish between repeated short-term infection and long-term persistence within defined 
tissues, because alternative modes of infection can be expected to provoke different types of 
immune response. Data from animal imaging models has led us to propose a model of 
continual parasitism of the GI tract that is tolerated by the host, combined with repeated, 
sporadic reinvasions of the heart and other sites, which provoke effective host responses. 
There is good evidence that chronically infected mice can efficiently control systemic 
parasites. C57BL/6 mice generate plentiful T. cruzi-specific CD8+ T cells with a cytotoxic, 
non-exhausted phenotype [80]. The number of interferon- γ (IFN-γ) producing T cells 
increases after high-dose intravenous secondary infection, concomitant with rapid clearance 
of parasites from the re-infected spleen, lung and liver [19]. Similarly, neither homologous 
nor heterologous superinfections of chronically infected C3H mice had a lasting impact on 
muscle tissue burdens [52]. Immunohistochemical detection of T. cruzi in chronic phase 
hearts typically reveals debris-like antigen deposits, and not intact organisms [21]. In terms 
of pathogenesis, the reinvasion model (Figure 1, Key Figure) could explain the lack of 
consistent correlation between tissue fibrosis (a cumulative, largely irreversible pathology) 
and ‘snapshot in time’ measurements, such as inflammation and local parasite load [34]. It 
may also lead to a better understanding of why the majority of Chagas disease deaths are 
attributed to sudden arrhythmic events or embolism, rather than chronic heart failure [95].
The logical next questions concern the source and mechanism of active (re-)infection foci 
and the consequent inflammatory responses in particular sites. Addressing this question is 
likely to be difficult given the requirement to track the movement of individual parasites 
between distant sites in vivo. It is not known how trypomastigotes transit between tissues 
and the circulation. The trypomastigote surface glycoprotein gp85 does have high avidity for 
vascular endothelial cells [96] and vasculitis can be a feature of chronic infections [84]. 
Nevertheless, superinfection experiments indicate that the majority of parasites entering the 
blood of chronically infected hosts are expected to be rapidly opsonized and cleared, mainly 
in the liver by Kupffer cells [19]. This would be particularly true for parasites exiting the GI 
tract into the portal venous system. Trafficking via the lymphatics could allow T. cruzi to 
circumvent the liver, promoting both dissemination and transmission. Pertinently, parasites 
or infected cells exiting the GI tract by a lymphatic route would drain into the subclavian 
vein and then directly encounter the right atrium. Imaging shows that mesenteric tissue is a 
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relatively frequent site of infection in mice [34], but it remains unclear whether live parasites 
can evade the firewall function of the mesenteric lymph nodes. Besides reinvasion by free 
trypomastigotes, several studies provide circumstantial evidence that trafficking of 
parasitized myeloid cells into organs could be important. T. cruzi antigens often localize to 
interstitial dendritic cells in the heart [97]. Peripheral infection foci typically appear and 
disappear over the course of hours, consistent with trafficking of infected host cells [16]. 
Furthermore, in a fatal acute infection model, parasite burdens in the heart depended on the 
ability of T. cruzi to replicate specifically in myeloid cells expressing Slamf1 [98], a surface 
receptor with a pro-migratory function [99, 100]. Lastly, it is important to acknowledge the 
possibility that reinvasion may occur alongside reactivation of (quasi)dormant parasite foci. 
Indeed, evidence for in vivo metabolic heterogeneity in other intracellular pathogens [38, 39] 
suggests this could be a vital, but largely unexplored aspect of T. cruzi biology.
Concluding Remarks
T. cruzi is a fascinatingly versatile microorganism. It parasitizes diverse cell types in 
multiple tissues, in hundreds of different mammal hosts, and is transmitted by dozens of 
triatomine vector species. This promiscuity makes T. cruzi infections challenging to study in 
both clinical and experimental settings (see Outstanding Questions). Nevertheless, 
increasingly sophisticated parasite detection technologies are leading to a better appreciation 
of the dynamic nature of chronic infections and how this intersects with Chagas disease 
pathogenesis. Host immune responses clearly enforce a dramatic restriction of the niches 
within which T. cruzi can persist. However, the mechanism(s) of long-term immune evasion 
within individual hosts remains largely unknown. Different modes of persistence may occur 
within and between organs, including continual low-level infection, dormancy-reactivation 
and episodic re-invasion. Distinguishing the contribution of these processes to long-term 
tissue-specific infection dynamics will require careful experimental investigation. An even 
greater challenge will be to analyse them in humans and define their contribution to the 
development of both cardiac and digestive Chagas disease.
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Box 1: Cured or not cured?
Identifying whether a patient or experimental animal has been cured of T. cruzi infection 
is a critical question, whether assessing the effectiveness of the front-line drugs 
(benznidazole or nifurtimox), or testing new chemotherapeutic agents and 
immunotherapies [72]. Detection of T. cruzi in humans is usually restricted to blood. 
Consequently, prediction of parasitological cure is normally based on the presence or 
absence of parasite-specific immunoglobulins or parasite DNA. Post-cure conversion to a 
seronegative status may take years to occur. Quantitative PCR can be sufficiently 
sensitive to detect a single parasite in 5 ml of blood [101]. However, the main utility of 
PCR is to confirm failure to cure, because even consistently negative results cannot prove 
that tissue parasites have been completely eliminated [2]. Ongoing investigation of a 
number of other biomarkers may expand the options available to monitor clinical 
interventions e.g. [24].
The increased sampling possibilities available for experimental animal models can 
potentially generate a greater degree of confidence in predicted cure rates [72]. 
Quantitative PCR is a powerful tool, but suffers from limitations arising from the focal 
and dynamic nature of chronic infections. Bioluminescence imaging models can 
overcome this problem, yet are subject to their own detection limits and will have a 
restricted ability to detect metabolically quiescent parasites. Dormant forms of T. cruzi 
are currently hypothetical and their role in disease progression would probably be minor. 
They could still be important for sustaining persistence though, and would be particularly 
concerning in the context of drug treatment. The use of immunosuppression in tests 
involving predictive animal models is therefore seen as an essential procedure because it 
leads to rapid expansion and dissemination of T. cruzi [33, 34, 75, 80, 94]. The most 
common protocol used in drug efficacy studies involves treatment of mice with 
cyclophosphamide, which is cytotoxic to many leukocyte populations. It is important to 
note that cyclophosphamide dosing regimens have never been systematically validated in 
the context of chronic T. cruzi infection. Nevertheless, consistently negative parasite 
detection tests conducted on multiple tissues, even after cyclophosphamide-induced 
immunosuppression, is currently the most convincing criterion of cure in murine models.
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Box 2: Chagas enteropathy, a most neglected disease?
Digestive forms of Chagas disease are characterised by progressive dilation of sections of 
the digestive tract, usually but not exclusively the oesophagus or colon. Cases are most 
common in Bolivia, Chile, northern Argentina and southern Brazil; and despite 
fragmentary data, the overall incidence is estimated at 10-15% of infected people [2]. 
Understanding of the molecular and cellular basis of pathogenesis lags far behind the 
advances made for chagasic cardiomyopathy. Dilation is associated with loss of neurons, 
dysperistalsis and hypertrophy, inflammation and fibrosis of the smooth muscle layers 
[102, 103]. The most common symptoms include difficult or painful swallowing, 
abdominal pain, constipation and faecaloma. Treatment options are limited to palliative, 
dietary and surgical interventions [2].
Anti-parasitic chemotherapy has not been considered justifiable for seropositive 
individuals with digestive symptoms, but normal heart function [104]. This is primarily 
because clinical trials have not addressed the efficacy of treatment in the context of 
digestive outcomes. It is also influenced by a prevailing view that megasyndromes result 
from irreversible enteric denervation during the acute phase [102, 105], in which anti-
parasitic inflammatory responses are thought to cause iNOS-dependent collateral damage 
to neurons [88]. Further age-related denervation is posited to gradually unmask the 
parasite-driven losses, leading to progressive organ dysfunction [105]. The finding that 
the colon and stomach are the primary reservoirs of T. cruzi infection in mice [16, 34] 
raises the possibility that local infection may in fact continue to influence the 
development of digestive forms of Chagas disease into the chronic phase. Indeed, 
histological analyses have identified persistence of parasites in GI samples in 20-50% of 
megaesophagus cases [106, 107] and, using PCR-based strategies, other authors have 
found T. cruzi DNA in 100% of such samples [108]. Long-term infection in the dog is 
considered a useful animal model of chagasic megasyndromes [109] and some features of 
nascent enteropathy can also be observed in experimentally infected mice [110]. These 
studies, amongst others, now form a framework for further experimental investigation, 
not only of the role of T. cruzi in digestive pathogenesis, but also of the ability of specific 
chemotherapy targeting the parasite to treat this type of Chagas disease.
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Outstanding Questions
• Why is T. cruzi preferentially able to parasitize myocytes in chronic 
phase infections?
• What are the mechanisms of long-term immune evasion?
• Is there a metabolically quiescent or dormant form of T. cruzi that may 
have a role in long-term persistence and perhaps treatment failure?
• Which modes of persistence occur in humans and how closely do they 
match the mouse model e.g. does the GI tract serve as a ‘safe haven’ 
for parasites and is heart infection episodic or continuous?
• What is the source of parasites when reactivation of Chagas disease 
occurs under immunosuppression? For example, are cutaneous and 
CNS pathologies due to local expansion of underlying infection or to 
re-invasion from other sites?
• What is the mechanism that drives the development of digestive 
megasyndromes and is it dependent on chronic persistence of T. cruzi 
within the GI tract?
• What is the identity and phenotype of the cells in the GI tract that act as 
reservoirs of infection?
• Will elimination of parasites from the gut reservoir lead to a sterile cure 
of chronic infections?
• Is immunotherapy an option for inducing immune-mediated killing of 
parasites in the sites of persistence?
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Trends Box
• Advances in the sensitivity and accuracy of molecular and imaging 
technologies are leading to a better understanding of quantitative, 
spatial and temporal variation in Trypanosoma cruzi infections.
• T. cruzi is pan-tropic in acute phase infections, with some strain-
specific heterogeneity in parasite loads between cell and tissue types.
• The gastrointestinal tract serves as the main parasite reservoir in mice 
during chronic infections; there is currently insufficient evidence to 
define long-term reservoirs in humans.
• Targeting myeloid cells for infection may allow T. cruzi to evade 
adaptive immune responses, re-invade tissues and achieve transmission.
• A model of repeated reinvasion of the heart has the potential to better 
explain chagasic cardiac pathology than one of continual local 
persistence.
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Figure 1. Key Figure. Modes of parasite persistence in long-term Trypanosoma cruzi infections
In chronic infections T. cruzi predominantly parasitizes myocytes. These infected cells are 
typically scarce and focally distributed; they can be within cardiac, skeletal or smooth 
muscle tissues, such as those from the vasculature or the gastrointestinal (GI) tract. The heart 
is the most common site of pathology. Parasite persistence within an individual host may 
occur through different modes: a) Continuous persistence describes an ever-present, low 
abundance parasite load that is sustained as a locally contained equilibrium between 
intracellular parasite replication and host immune responses; b) Although they have not been 
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proven to exist, dormant forms of T. cruzi may reside within tissues and evade host 
immunity. As seen for other pathogens, reactivation into typical replication cycles could 
occur on an intermittent basis; c) Due to the ability of T. cruzi to invade multiple tissues and 
migrate between them, an organ may be subject to discrete episodes of infection by 
reinvasion. These three modes are not mutually exclusive and may overlap to different 
degrees at different times. Over time, the cumulative parasite load is likely to dictate the 
frequency and intensity of local inflammatory responses, which, depending on their quality, 
result in differing degrees of pathology. The figure is intentionally simplified and does not 
convey the molecular and cellular complexity of Chagas disease immunopathogenesis.
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Figure 2. Model for a link between host-parasite genetics, infection dynamics and chagasic 
cardiac pathology
In experimental murine models of chronic Trypanosoma cruzi infection, varying host and 
parasite genotype combinations can generate different severities of cardiac pathology. Real-
time in vivo imaging studies of tissue-specific infection dynamics [16, 34] have suggested 
that an important factor is the extent of parasite dissemination. Regions of the 
gastrointestinal (GI) tract serve as permanent reservoirs of infection, especially the proximal 
large intestine and stomach, regardless of the host-parasite genotype combination. The 
photos show ex vivo imaged GI tracts overlaid with pseudocolour heat-maps of 
bioluminescence intensity, which is used as a proxy for parasite numbers. Other tissue sites, 
including the heart, are actively infected more sporadically. Some models, such as C57BL/6 
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mice infected with a T. cruzi type VI strain (CLBR) have low parasite burdens outside the 
gut, heart infection is relatively infrequent and cardiac fibrosis is relatively mild. Other 
models, particularly C3H/HeN mice with chronic T. cruzi type I infections, have more 
broadly disseminated infections, frequent infection foci localized to the heart and more 
severe cardiac fibrosis.
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Table 1
Common methods for detection of Trypanosoma cruzi in mammalian hosts
Method Target Main Advantages Main Drawbacks Example
Refs
Serology Anti-parasite
antibodies
Simple, low cost
Diagnostic gold
standard
Indirect, qualitative
Long time to
seronegativisation
in cured subjects
[9, 10, 25,
58, 79, 97]
Fresh blood
microscopy
Live
trypomastigotes
Definitive
Fast result
Mainly restricted to
acute phase
Blood poor proxy
for tissue
[98]
Haemoculture Live parasites Low cost
Definitive
Long time until
result
Low sensitivity
[18]
Xenodiagnosis Live parasites Low cost
Definitive
Long time until
result
Requires triatomine
colony
[111]
Histology Intact fixed
organisms
Parasites seen directly
in situ
Morphological and
pathological context
available
Low sensitivity
Sampling bias a
Snapshot data
[3, 4, 19,
20, 41, 59,
61, 73, 98]
Immunohistochemistry Parasite antigen More sensitive than
routine histology
Semi-quantitative
Morphological and
pathological context
available
Careful
optimisation of
signal and
background needed
Sampling bias a
Snapshot data
[21, 61,
66, 69, 97]
PCR Parasite DNA High sensitivity
Lowest limit of
detection
Can be quantitative
Some targets allow
discrimination of T.
cruzi subtypes
Sampling bias a
Snapshot data
Risk of
contamination or
non-specific
amplification
generating false
positive results
[6, 16, 17,
19, 22, 23,
52, 57, 61,
66-68, 75-
77, 84,
101]
Bioluminescence /
Fluorescence Imaging
Transgene
expression in
live parasites
Allows serial
evaluation
Can be highly
sensitive
Minimal tissue
sampling bias
Only live parasites
detected
Animal models only
High cost
Requires
optimisation of
transgene
expression
[26-29,
32-34]
aOwing to the variability in distribution of parasite foci over time and between tissue sites.
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